Esperion Therapeutics GAAP EPS of $0.22 misses by $0.05, revenue of $168.45M beats by $2.33M
Source: SeekingAlpha
2026-03-10 06:10:32 ET
More on Esperion Therapeutics
- Esperion Therapeutics, Inc. (ESPR) Corstasis Therapeutics, - M&A Call - Slideshow
- Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript
- Esperion Therapeutics: Past The Turnaround, Waiting On Guidelines
- Esperion Therapeutics Q4 2025 Earnings Preview
- Esperion to acquire Corstasis for $75M upfront payment
Read the full article on Seeking Alpha
For further details see:
Esperion Therapeutics GAAP EPS of $0.22 misses by $0.05, revenue of $168.45M beats by $2.33M
Esperion Therapeutics Inc.
NASDAQ: ESPR
ESPR Trading
-5.87% G/L:
$2.755 Last:
5,824,220 Volume:
$3.12 Open:
ESPR Latest News
March 10, 2026 06:00:00 am
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ESPR Stock Data
$804,448,466
234,999,359
0.16%
70
N/A
Pharmaceuticals
Healthcare
US
Ann Arbor
